New York, N.Y.; and Herzliya, Israel From Lorenc Aesthetic Plastic Surgery and ColBar LifeScience Ltd.
Plast Reconstr Surg. 2010 Jun;125(6):1805-1813. doi: 10.1097/PRS.0b013e3181d0ac75.
Injectable dermal fillers have become important alternatives to traditional surgical procedures for the correction of facial wrinkles and restoration of facial volume. The physical properties of a dermal filler/volumizing agent, and the host tissue response to the agent, influence its clinical performance and patient outcomes.
In this study, several key physical properties of the new porcine collagen dermal filler Dermicol-P35 27G were measured and compared with those of commercially available hyaluronic acid-based dermal fillers. Furthermore, the in vivo properties of implanted Dermicol-P35 27G were evaluated by histologic and histopathologic methods.
This study found that Dermicol-P35 27G provides a lower extrusion force profile and yield point compared with the hyaluronic acid-based dermal fillers tested. At 2 years, staining of punch biopsy specimens with hematoxylin and eosin and Herovici stains revealed no inflammatory cells and no evidence of other adverse events in any of the samples containing Dermicol-P35 27G. Within-implant colonization by fibroblasts depositing new collagen and the formation of elastin within the implanted collagen material (as shown by Luna staining) suggest that Dermicol-P35 27G is a bioactive implant.
Compared with several hyaluronic acid-based dermal fillers, Dermicol-P35 exhibited lower extrusion force, higher viscosity under low shear rate, and a higher modulus of elasticity. Results of histologic evaluation indicated that Dermicol-P35 27G did not elicit an inflammatory response and was well integrated within the host tissue. Together, these results suggest that Dermicol-P35 27G offers several advantages that may result in improved clinical experiences for both patients and clinicians.
注射用真皮填充剂已成为传统手术矫正面部皱纹和恢复面部体积的重要替代方法。真皮填充剂/体积增大剂的物理特性以及宿主组织对该剂的反应会影响其临床性能和患者结局。
本研究测量了新型猪源胶原蛋白真皮填充剂 Dermicol-P35 27G 的几个关键物理特性,并将其与市售的透明质酸真皮填充剂进行了比较。此外,还通过组织学和组织病理学方法评估了植入 Dermicol-P35 27G 的体内特性。
本研究发现,与所测试的透明质酸真皮填充剂相比,Dermicol-P35 27G 提供了较低的挤出力曲线和屈服点。在 2 年时,苏木精-伊红和 Herovici 染色的打孔活检标本未见炎症细胞,且任何含有 Dermicol-P35 27G 的样本均未见其他不良事件的证据。植入物内的成纤维细胞沉积新的胶原蛋白并在植入的胶原蛋白材料内形成弹性蛋白(如 Luna 染色所示)表明 Dermicol-P35 27G 是一种生物活性植入物。
与几种透明质酸真皮填充剂相比,Dermicol-P35 表现出较低的挤出力、在低剪切速率下更高的粘度和更高的弹性模量。组织学评估结果表明,Dermicol-P35 27G 不会引起炎症反应,并且与宿主组织很好地整合在一起。这些结果表明,Dermicol-P35 27G 具有若干优势,可能会为患者和临床医生带来更好的临床体验。